In patients with severe heart failure who undergo left ventricular assist device implantation, the MELD score is significantly associated with perioperative transfusion requirements, severe morbidity, and death.
Do Omega-3-Acid Ethyl Esters Help Achieve Lipid Targets?

Effects of Prescription Omega-3-Acid Ethyl Esters on Non-High-Density Lipoprotein Cholesterol When Coadministered
With Escalating Doses of Atorvastatin. Bays HE, McKenney J, et al: Mayo Clin Proc 2010; 85 (February): 122-128 In patients with elevated non-HDL cholesterol, the addition of an omega-3-acid ethyl ester to statin therapy can increase HDL and lower triglycerides.
Background: Current recommendations target low-density lipoprotein (LDL) as the primary goal of lipidlowering therapy. In patients with elevated triglycerides, secondary goals for non-high-density lipoprotein (non-HDL) are recommended. Prescription omega-3-acid ethyl esters (P-OM3) such as Lovaza have been effective in lowering triglycerides. Objective: To determine the impact of adding P-OM3 to escalating doses of a statin on non-HDL-C and other lipid parameters. Design: Randomized, double-blind, placebo-controlled study. Participants: Men and women between the ages of 18 and 79 years with non-HDL-C >160 mg/dL and triglycerides between 250 and 599 mg/dL were eligible. Methods: All patients underwent a 4-week lead-in, during which lipid-altering medications were discontinued. Participants were randomized to receive P-OM3 4 g/day for 16 weeks or a matching placebo. All participants received open-label atorvastatin 10 mg for the first 8 weeks, followed by 20 mg for 4 weeks and 40 mg for 4 weeks. The primary end point was the percent change in non-HDL-C between baseline and week 8. Other secondary end points included changes from baseline in total cholesterol, HDL-C, LDL-C, and triglycerides at weeks 12 and 16. Results: 245 participants were randomized. Average age was 56 years, and average body mass index was 30; 56% were men, and approximately 90% were white. At baseline, total cholesterol was approximately 250 mg/dL, HDL-C was 37 mg/dL, LDL-C was 140 to 146 mg/dL, and triglycerides were 315 to 348 mg/dL. At 8 weeks, in the P-OM3 group, the non-HDL-C had decreased 40% (from 213 to 133 mg/dL) compared to 34% with atorvastatin alone (215 to 142 mg/dL). At both 12 and 16 weeks, the non-HDL-C was significantly lower in the P-OM3 group. At 16 weeks, the combination of P-OM3 and atorvastatin did not affect LDL-C compared to placebo, but HDL-C was 6% higher and triglycerides were 19% lower. In the post-hoc analysis, there were no significant differences in the rates of achieving lipid targets. Comparing the P-OM3 group to placebo, 86% versus 92% achieved their LDL-C target, and 89% versus 88% achieved their non-HDL-C target. Adverse effects were rare.
Conclusions:
The addition of a P-OM3 to atorvastatin did reduce the non-HDL-C compared to atorvastatin alone. However, in the group studied, the majority of subjects met both their LDL-C and non-HDL-C goals with atorvastatin alone. Reviewer's Comments: In this industry-sponsored study, the role of an omega-3-acid ethyl ester (Lovaza) in improving the non-HDL-C was examined. Certainly, the addition of the P-OM3 did show modest improvements in HDL-C and triglycerides. However, nearly all patients met their lipid goals on a statin alone. Therefore, until there are more clinical data on the efficacy of P-OM3 therapy (and other omega-3 products), I will continue to use them primarily for severe hypertriglyceridemia, and consider them when the non-HDL-C goal is not met with statin treatment. (Reviewer-Mark E. Pasanen, MD). In a large cohort of diabetic patients, the lowest mortality was found with an A1C of 7.5%.
More Data Support Increased Mortality With Low A1C in Type 2 Diabetes
Background:
The ideal hemoglobin A1C for patients with type 2 diabetes is controversial. Recent studies have suggested increased mortality with low hemoglobin A1C. Design: Retrospective cohort study. Participants: 47,970 patients in the United Kingdom who had their diabetes regimen intensified between November 1986 and November 2008. Patients were divided into 2 groups: cohort 1, in which patients had been treated with combination oral therapy (either adding metformin to a sulfonylurea or vice versa), or cohort 2, in which patients had been started on insulin.
Methods:
The 2 cohorts were stratified into 10 groups based on the patient's average hemoglobin A1C for the remainder of the study period. These deciles ranged from an average A1C of 6.38% in the lowest decile up to 10.56% in the highest. The primary end point of the study was all-cause mortality. Results/Conclusions: In both groups, mortality was lowest with an average hemoglobin A1C of 7.5. In the oral agent cohort, the hazard ratio for mortality was 1.3 in the lowest decile compared to 7.5%, and was 1.93 in the highest. In the insulin cohort, it was 1.79 in the lowest and 1.80 in the highest. Reviewer's Comments: This study adds additional data to the discussion of target hemoglobin A1C in type 2 diabetics. I like that its findings make some intuitive sense: if the excess mortality in the low A1C group is related to hypoglycemia, it follows that insulin would be higher risk than oral agents. It may also reflect that the insulin-treated group had more severe disease or more co-morbidities. Combining this with the United Kingdom Prospective Diabetes Study results, it suggests that, with younger patients who are early in their illness, it may make sense to go for a low A1C, particularly if one can get there with an insulin sensitizer that has a low risk of hypoglycemia. As patients get older and develop other co-morbid conditions, it may be reasonable to allow a slightly higher A1C to avoid complications of overtreatment, especially if it seems like diabetes may not be the patient's life-limiting illness. I expect we will see continued debate and continued studies on this issue given the conflict in the current literature. (Reviewer-Christopher L. Knight, MD). Daily suppressive acyclovir does not reduce HIV transmission by those co-infected by HIV and HSV-2.
Acyclovir --Disappointing in Prevention of HIV Transmission
Acyclovir and Transmission of HIV-1 From Persons Infected with HIV-1 and HSV-2.
Background: Most people infected by HIV are also infected with HSV-2. HSV reactivation is associated with higher HIV levels in blood and genital secretions, and symptomatic genital ulcers increase the risk of HIV transmission.
Objective: To determine whether suppression of HSV-2 reactivation with chronic acyclovir therapy would decrease the risk of transmission of HIV. Design: Randomized, placebo-controlled trial. Participants: 3408 couples discordant for HIV infection at 14 sites in Africa; 68% of the HIV-infected partners were women. Methods: Stable couples in which only one partner was infected with HIV were recruited at 14 sites in southern and east Africa. The HIV-infected partner had to have a CD4 count of ≥250, have no AIDS-related illnesses, and be on no antiretroviral therapy. Persistent genital ulcers, ongoing acyclovir use, and pregnancy were also exclusion criteria. The HIV-infected partners were randomized to acyclovir 400 mg twice a day versus placebo, distributed at monthly visits for up to 24 months. Adherence, high-risk sexual activity, and symptoms of genital herpes were assessed monthly. Patients with ulcers were given open-label acyclovir for 5 days in addition to the study drug.
Results:
The 2 groups were similar at baseline; 76% of the couples were married, and 90% lived together. The partners had a mean of 6 sexual contacts in the month before enrollment. Pill counts showed that adherence was excellent, and acyclovir patients had lower HIV viral loads and 73% fewer outbreaks of genital ulcers. One hundred and thirty-two uninfected partners had HIV seroconversion; however, in 38 cases, the HIV virus was not genetically linked to the partner's strain, suggesting transmission from someone else. Acyclovir did not have a significant effect on the likelihood of HIV transmission (HR with acyclovir, 0.92).
Conclusions: Acyclovir suppression of HSV-2 did not reduce HIV transmission, despite a reduction in HIV viral load and in genital ulcers. Reviewer's Comments: This is a disappointingly negative study of a cheap and well-tolerated idea for preventing HIV transmission. The acyclovir was certainly effective in preventing herpes outbreaks, but patients should not be reassured that this makes them any less infectious. (Reviewer-Karen A. McDonough, MD). Results: 875 women completed the questionnaire, yielding a response rate of 41%. Of these women, 461 patients (52.6%) were noted to have had urinary incontinence in the past 12 months, while 340 (38.9%) had had symptoms in the past 7 days. When adjusted for age, the prevalence of undiagnosed incontinence was 51% in the past 12 months and 38% for the past 7 days. Younger women tended to have stress incontinence and older women were more likely to have mixed or urge incontinence. Severity of incontinence was measured by the Sandvik Severity Index, which incorporates frequency and amount of leakage. Symptom severity was correlated with worse quality of life. A total of 234 women had moderate to severe symptoms; of these, only 11 women (4.7%) had documentation of urinary incontinence in the medical record, despite 4 median office contacts and 2 median telephone contacts. Conclusions: Urinary incontinence is a largely unrecognized and untreated condition in women, with potential for considerable impact on quality of life. Reviewer's Comments: This study validates previous reports that identify a number of barriers to care for urinary incontinence, including fear of medical intervention, legitimacy of symptoms as medical problems, and embarrassment surrounding the condition. This survey was limited in its response rate of 41%, as it is unclear if a selection bias may have been introduced. For example, nonresponders may have chosen not to respond despite symptoms, or they may not have had symptoms, leaving them less motivated to participate. However, responses did suggest significant impact of symptom severity on quality of life, and apparently significant underreporting of symptoms to care providers despite multiple episodes of care. Incontinence in older populations may be associated with depression, decreased mobility, and even institutionalization. Awareness of this underreported condition may help prompt earlier care and relatively simple interventions. (ReviewerEmily Y. Wong, MD).
10-Year Follow-Up of the Euro-Lupus Nephritis Trial
The 10 Long-term follow-up (10 years) of the landmark Euro-Lupus Nephritis Trial shows that a low-dose cyclophosphamide induction regimen results in comparable outcomes compared to higher dose regimens.
Background: Patients with lupus nephritis are commonly treated with induction therapy with cyclophosphamide (CY) or mycophenolate mofetil, in combination with prednisone. The Euro-Lupus Nephritis Trial (ELNT), first published in 2002, showed that lower doses of CY given for shorter induction periods were equivalent to higher dose induction regimens. It is necessary to follow patients with lupus nephritis for longer periods of time to capture important end points, such as progression of renal insufficiency or development of end-stage renal disease (ESRD).
Objective: This publication provides longer term follow-up for the ELNT study population. Participants/Methods: 90 adult patients with moderately severe proliferative lupus nephritis and ≥500 mg of proteinuria per 24 hours were randomized to a standard tapering glucocorticoid regimen plus high-dose (HD) or low-dose (LD) intravenous cyclophosphamide (IVCY). HD IVCY consisted of 6 monthly pulses of 0.5 gm/m2 followed by 2 quarterly pulses. CY doses were increased to a maximum of 1500 mg per pulse if tolerated by measuring the day 14 white blood cell count nadir. The LD regimen consisted of 6 pulses of 500 mg of IVCY given every 2 weeks. In both groups, azathioprine was given as maintenance therapy after induction was completed. The principal end points were doubling of baseline serum creatinine (Cr), development of ESRD, or death. Results: Only 6 patients were lost to follow-up over an average of 10 years of follow-up (3 in each group). There was no statistically significant difference in the risk of developing doubling of serum Cr, ESRD, or death between the 2 groups. There was no difference in the serum Cr and 24-hour proteinuria between the 2 groups. Patients in the LD IVCY group received a significantly lower cumulative dose of CY than the HD group (5.5 gm vs 9.5 gm, respectively; P <0.001). Unexpectedly, more cancers were found in the LD group at an average follow-up of 100 months, although this difference did not reach statistical significance. Conclusions: Patients with moderately severe lupus nephritis treated with low-dose IVCY enjoyed similar results compared to patients treated with traditional higher-dose regimens. Reviewer's Comments: The "Euro-Lupus" low-dose IVCY regimen has become one of the accepted standard induction regimens for lupus nephritis (mycophenolate induction is an alternative). The important result of this study is that major outcomes did not differ between LD and HD regimens. Exposure to lower doses of CY might be associated with lower risks of side effects, including infection, impaired fertility, and secondary malignancies. The finding that more cancers were diagnosed in the low-dose group was unexpected and will need to be followed with ongoing clinical experience. (Reviewer-Paul R. Sutton, PhD, MD).
How to Minimize Jet Lag
Jet Lag. Background: Jet lag is a benign problem, but daytime sleepiness, nighttime insomnia, and grumpiness can certainly make the first few days of a vacation or business trip less fun. Objective: To outline strategies for managing jet lag. Results: The author suggests 3 treatment strategies, which may be combined. First, the circadian rhythm may be reset by strategic light exposure, melatonin or both. For eastward travel, bright daylight first thing in the morning will shift the body clock to the new, earlier wake up time. Melatonin 0.5 to 3 mg should be taken at the new bedtime. For westward travel, bright light in the evening will move the endogenous bedtime later. A lower and shorter acting dose of melatonin, 0.5 mg, should be taken if awake in the second half of the night to help the traveler sleep later. Second, the timing and duration of sleep should be optimized. Before leaving, shift the sleep schedule 1 to 2 hours toward the destination time zone to shorten jet lag. Daytime naps should be kept short to avoid messing up nighttime sleep. Third, hypnotics such as zolpidem can help travelers get to sleep for the first 3 to 4 nights after arrival when travelling east. The author suggests caution in using hypnotics during a flight, as the traveler may wake up at their destination quite groggy and confused. Not surprisingly, caffeine is suggested to promote alertness during the day, but not too close to bedtime. Crossing more than 8 to 10 time zones is even more challenging for the circadian clock to adapt to. In this case, for the first 2 days, bright daylight should also be avoided at times it might inhibit adaptation: for several hours before dusk if travelling west and several hours after dawn if travelling east. Since it is easier to move the body's clock backward than forward, some experts suggest treating all flights across more than 8 to 10 time zones as westward travel. Conclusions: Travelers (and physicians) crossing several time zones have several strategies that can minimize jet lag. Reviewer's Comments: This is a sensible, easy to read summary with a table that clearly outlines recommendations in terms non-physician travelers can probably understand. Apart from the author's suggestion, "Do not leave packing and other travel preparations to the last minute," I will follow them for my next long trip. (Reviewer-Karen A. McDonough, MD).
